LFCR Q2 2023 Earnings — Lifecore Biomedical, Inc. Revenue & Financial Results | Market Cap Arena

LFCRLifecore Biomedical, Inc.

$267M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$22M-49.7% YoY

Gross Profit

$6M26.0% margin

Operating Income

-$5M-24.5% margin

Net Income

-$13M-58.6% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

-7.8%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$6M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$279M

Total Liabilities

$205M

Stockholders' Equity

$74M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$43M	-49.7%
Gross Profit	$6M	$15M	-61.4%
Operating Income	-$5M	$4M	-229.3%
Net Income	-$13M	-$38M	+66.7%

Geographic Segments

SWITZERLAND

$4M44%

CANADA

$3M29%

IRELAND

$1M11%

CZECHIA

$1M11%

All Other Countries

$500,0005%